Modification of the Incidence of Drug-Associated Symmetrical Peripheral Neuropathy by Host and Disease Factors in the HIV Outpatient Study Cohort
Open Access
- 1 January 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 40 (1) , 148-157
- https://doi.org/10.1086/426076
Abstract
Background. We sought to identify factors associated with the clinical diagnosis of symmetrical peripheral neuropathy (SPN) during the era of highlyKeywords
This publication has 29 references indexed in Scilit:
- The Cellular Pharmacology of Nucleoside‐ and Nucleotide‐Analogue Reverse‐Transcriptase Inhibitors and Its Relationship to Clinical ToxicitiesClinical Infectious Diseases, 2004
- Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individualsAIDS, 2003
- Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicityClinical Therapeutics, 2000
- Neuromuscular function in HIV infectionAIDS, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Peripheral Neuropathy with Nucleoside AntiretroviralsDrug Safety, 1998
- Human immunodeficiency virus infection of dorsal root ganglion neurons detected by polymerase chain reaction in situ hybridizationAnnals of Neurology, 1997
- Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cellsJournal of the Neurological Sciences, 1997
- Low-dose zalcitabine-related toxic neuropathyNeurology, 1996
- Increased NADPH-diaphorase reactivity and cytokine expression in dorsal root ganglia in acquired immunodeficiency syndromeJournal of the Neurological Sciences, 1996